Cephalon Inc. / Anesta Corp.

Breakthrough Cancer Pain

$55M Actiq US sales projection 2001 (analyst estimate at deal time)

Disease Overview

Breakthrough cancer pain is a transient flare of severe pain that breaks through scheduled around-the-clock opioid therapy in patients with chronic cancer pain. It typically peaks within minutes and subsides within an hour, demanding rapid-onset rescue analgesia that conventional oral opioids cannot deliver fast enough.

Competitive Landscape

At the July 2000 Cephalon-Anesta deal, Actiq (oral transmucosal fentanyl citrate, OTFC) was the first and only rapid-onset fentanyl approved for breakthrough cancer pain, FDA-cleared in 1998 and launched March 1999. The standard of care for breakthrough cancer pain otherwise consisted of immediate-release oral morphine, oxycodone, and hydromorphone — all of which had 30-45 minute onset, mismatched to the kinetics of breakthrough episodes. Anesta had recovered Actiq rights from Abbott in March 2000 after the Abbott-Alza merger collapsed on antitrust grounds, putting full commercial control back with a small specialty company that lacked an oncology sales force. The $444M all-stock deal ($31.45/share, 0.4765 Cephalon shares per Anesta share) gave Cephalon a 60-rep oncology field force to co-promote Actiq alongside Provigil (modafinil). Analyst Peter Ginsberg (US Bancorp Piper Jaffray) rated Cephalon a 'strong buy,' projecting Actiq sales of ~$16M in 2000 ramping to ~$55M in 2001. The deal also positioned Cephalon for the eventual Fentora (fentanyl buccal tablet) lifecycle extension, though later rapid-onset fentanyl entrants (Onsolis, Abstral, Lazanda, Subsys) and REMS-driven prescribing constraints capped the category long-term.